- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01046877
Singapore Tympanostomy Tube Delivery System Study
January 4, 2015 updated by: Acclarent
A Clinical Study of the Acclarent Tympanostomy Tube Delivery System For The Treatment of Patients Requiring Tympanostomy Tube Insertion For Otitis Media
The objective of the study is to evaluate the safety and efficacy of the Acclarent Tympanostomy Tube Delivery System (TTDS) in the placement of tympanostomy tubes (TTs) in patients indicated for such treatment for chronic otitis media with effusion (OME) or recurrent acute otitis media (AOM).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore
- KK Women's and Children's Hospital Singapore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- >= 1 year of age
- Diagnosed with either Chronic Otitis Media with Effusion or recurrent Acute Otitis Media and scheduled to undergo bilateral or unilateral tympanostomy tube insertion.
- Either male or female -
Exclusion Criteria:
- History of sensitivity or reaction to anaesthesia
- Markedly atrophic, retracted, atelectatic or perforated tympanic membrane.
- Otitis externa
- Active acute otitis media
- Thickened Tympanic Membrane
- Thick mucoid effusion (also known as "glue ear")
- Otitis media pathology requiring T-tubes -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tympanostomy Tube placement
Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
|
Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Ears Treated Successfully With the TTDS in the Absence of Acute Intraprocedural Adverse Events.
Time Frame: Procedural
|
TTDS success will be confirmed by the successful delivery of a tube to the tympanic membrane.
|
Procedural
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Tympanostomy Tubes Extruded at 12 Months Post Procedure
Time Frame: 12 months
|
12 months
|
|
Percentage of Patent Tubes
Time Frame: 30 days
|
This measure assesses the patency (openness or lack of obstruction) of unextruded tubes.
|
30 days
|
Percentage of Patent Tubes
Time Frame: 3 months
|
This measure assesses the patency (openness or lack of obstruction) of unextruded tubes.
|
3 months
|
Percentage of Patent Tubes
Time Frame: 6 months
|
This measure assesses the patency (openness or lack of obstruction) of unextruded tubes.
|
6 months
|
Percentage of Patent Tubes
Time Frame: 9 Months
|
This measure assesses the patency (openness or lack of obstruction) of unextruded tubes.
|
9 Months
|
Percentage of Ears With Adverse Events
Time Frame: 30 days
|
This outcome measure evaluates occurrence of new adverse events since prior follow-up visit.
(non-cumulative)
|
30 days
|
Percentage of Ears With Adverse Events
Time Frame: 3 months
|
This outcome measure evaluates occurrence of new adverse events since prior follow-up visit.
(non-cumulative)
|
3 months
|
Percentage of Ears With Adverse Events
Time Frame: 6 months
|
This outcome measure evaluates occurrence of new adverse events since prior follow-up visit.
(non-cumulative)
|
6 months
|
Percentage of Ears With Adverse Events
Time Frame: 9 months
|
This outcome measure evaluates occurrence of new adverse events since prior follow-up visit.
(non-cumulative)
|
9 months
|
Percentage of Ears With Adverse Events
Time Frame: 12 months post procedure
|
This outcome measure evaluates occurrence of new adverse events since prior follow-up visit.
(non-cumulative)
|
12 months post procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Henry Tan, MD, KK Women's and Children's Hospital, Singapore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Actual)
August 1, 2010
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
January 11, 2010
First Submitted That Met QC Criteria
January 11, 2010
First Posted (Estimate)
January 12, 2010
Study Record Updates
Last Update Posted (Estimate)
January 15, 2015
Last Update Submitted That Met QC Criteria
January 4, 2015
Last Verified
January 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPR005004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Otitis Media
-
David Chi, MDRecruitingRecurrent Acute Otitis Media | Chronic Otitis Media With Effusion | Otitis Media in ChildrenUnited States
-
Bezmialem Vakif UniversityCompleted
-
Alcon ResearchCompletedOtitis Media With Effusion in Children | Otitis Media Recurrent
-
Medical College of WisconsinNational Institutes of Health (NIH); National Institute on Deafness and Other... and other collaboratorsRecruitingOtitis Media | Otitis Media With Effusion | Otitis Media AcuteUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedChronic Serous Otitis Media, Simple or UnspecifiedFrance
-
Tusker MedicalCompletedAOM - Acute Otitis Media | OME - Otitis Media With EffusionUnited States, Canada
-
University Hospital, GhentWithdrawn
-
Yuinvent Innovations Ltd.UnknownOtitis Media With Effusion
-
AcclarentCompletedOtitis Media With EffusionUnited States
-
Nazan DegirmenciCompleted
Clinical Trials on Tympanostomy Tube Delivery System
-
AcclarentCompletedOtitis Media With EffusionUnited States
-
AcclarentCompleted
-
Preceptis Medical, Inc.Completed
-
AcclarentCompletedOtitis Media With Effusion | Acute Otitis MediaUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingOtitis Media With Effusion After Nasopharyngeal CarcinomaChina
-
Zealand University HospitalDanish Medical AssociationCompletedQuality of Life | Sleep | Otitis Media With Effusion in ChildrenDenmark
-
Eye & ENT Hospital of Fudan UniversityChildren's Hospital of Fudan University; Xinhua Hospital, Shanghai Jiao Tong...Not yet recruitingOtitis Media With Effusion in Children
-
Preceptis Medical, Inc.CompletedOtitis Media | Ear InfectionUnited States
-
Preceptis Medical, Inc.Completed